trial

Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry

NCTId NCT00986167
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Unknown
Enrollment 72 (estimated)
Sponsored by Bayside Health
Primary completion 2010-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Unknown
Enrollment
72 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2009-10
Primary completion
2010-10
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Quetiapine

Sponsors

Bayside HealthLead Sponsor
AstraZenecaCollaborator

Investigators

1
Professor Jayashri KulkarniPrincipal Investigator

Sites

2 total
Fitzroy, AustraliaMelbourne, Australia

Facts & assertions

4 sourced
Enrollment
72
Phase
PHASE4
Primary Completion Date
2010-10
Status
UNKNOWN
relationships
The graph out of here
drug
Quetiapine
drug
lead_sponsor
Bayside Health
company
collaborator
AstraZeneca
company
indication
Aggression
indication
Psychosis
indication
Psychotic Disorders
indication
investigator
Professor Jayashri Kulkarni
person